News coverage about Quotient (NASDAQ:QTNT) has been trending somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Quotient earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.804703137293 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Several equities research analysts have commented on the stock. Zacks Investment Research cut shares of Quotient from a “hold” rating to a “sell” rating in a research report on Thursday, November 2nd. Jefferies Group cut their price target on shares of Quotient from $15.00 to $13.00 and set a “buy” rating on the stock in a research report on Wednesday, November 1st. Finally, BTIG Research reissued a “buy” rating and set a $12.00 price target on shares of Quotient in a research report on Wednesday, November 1st.

Shares of Quotient (QTNT) traded up $0.04 during trading hours on Friday, reaching $4.12. 485,538 shares of the company’s stock traded hands, compared to its average volume of 277,686. The company has a quick ratio of 0.86, a current ratio of 1.36 and a debt-to-equity ratio of -5.17. Quotient has a 52-week low of $3.22 and a 52-week high of $7.74. The company has a market cap of $185.88, a PE ratio of -1.43 and a beta of 1.40.

In other Quotient news, insider D J. Paul E. Cowan sold 45,000 shares of the business’s stock in a transaction dated Tuesday, October 17th. The shares were sold at an average price of $4.55, for a total transaction of $204,750.00. Following the sale, the insider now directly owns 26,666 shares of the company’s stock, valued at approximately $121,330.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider D J. Paul E. Cowan sold 30,197 shares of the business’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $4.92, for a total transaction of $148,569.24. Following the sale, the insider now directly owns 26,666 shares in the company, valued at $131,196.72. The disclosure for this sale can be found here. Insiders have sold a total of 175,197 shares of company stock worth $817,319 over the last three months. Insiders own 29.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Quotient (QTNT) Getting Somewhat Favorable Media Coverage, Report Shows” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2018/01/13/quotient-qtnt-getting-somewhat-favorable-media-coverage-report-shows.html.

Quotient Company Profile

Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.

Insider Buying and Selling by Quarter for Quotient (NASDAQ:QTNT)

Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.